Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.

Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vaccine against Alzheimer's disease (AD). In preparation of this vaccine, we sensitized the isolated dendritic cells ex vivo with Aβ peptide, and administered these sensitized dendritic cells as a the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Neel R Nabar, Fang Yuan, Xiaoyang Lin, Li Wang, Ge Bai, Jonathan Mayl, Yaqiong Li, Shu-Feng Zhou, Jinhuan Wang, Jianfeng Cai, Chuanhai Cao
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b3d47ae47c0f4d59b889ae0486f25323
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b3d47ae47c0f4d59b889ae0486f25323
record_format	dspace
spelling	oai:doaj.org-article:b3d47ae47c0f4d59b889ae0486f253232021-11-18T08:06:31ZCell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.1932-620310.1371/journal.pone.0049468https://doaj.org/article/b3d47ae47c0f4d59b889ae0486f253232012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23226497/?tool=EBIhttps://doaj.org/toc/1932-6203Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vaccine against Alzheimer's disease (AD). In preparation of this vaccine, we sensitized the isolated dendritic cells ex vivo with Aβ peptide, and administered these sensitized dendritic cells as a therapeutic agent. This form of cell therapy has had success in preventing and/or slowing the rate of cognitive decline when administered prior to the appearance of Aβ plaques in PDAPP mice, but has not been tested in 2 × Tg models. Herein, we test the efficacy and safety of this vaccine in halting and reversing Alzheimer's pathology in 9-month-old APP + PS1 mice. The results showed that administration of this vaccine elicits a long-lasting antibody titer, which correlated well with a reduction of Aβ burden upon histological analysis. Cognitive function in transgenic responders to the vaccine was rescued to levels similar to those found in non-transgenic mice, indicating that the vaccine is capable of providing therapeutic benefit in APP+PS1 mice when administered after the onset of AD pathology. The vaccine also shows indications of circumventing past safety problems observed in AD immunotherapy, as Th1 pro-inflammatory cytokines were not elevated after long-term vaccine administration. Moreover, microhemorrhaging and T-cell infiltration into the brain are not observed in any of the treated subjects. All in all, this vaccine has many advantages over contemporary vaccines against Alzheimer's disease, and may lead to a viable treatment for the disease in the future.Neel R NabarFang YuanXiaoyang LinLi WangGe BaiJonathan MaylYaqiong LiShu-Feng ZhouJinhuan WangJianfeng CaiChuanhai CaoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 12, p e49468 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Neel R Nabar Fang Yuan Xiaoyang Lin Li Wang Ge Bai Jonathan Mayl Yaqiong Li Shu-Feng Zhou Jinhuan Wang Jianfeng Cai Chuanhai Cao Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.
description	Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vaccine against Alzheimer's disease (AD). In preparation of this vaccine, we sensitized the isolated dendritic cells ex vivo with Aβ peptide, and administered these sensitized dendritic cells as a therapeutic agent. This form of cell therapy has had success in preventing and/or slowing the rate of cognitive decline when administered prior to the appearance of Aβ plaques in PDAPP mice, but has not been tested in 2 × Tg models. Herein, we test the efficacy and safety of this vaccine in halting and reversing Alzheimer's pathology in 9-month-old APP + PS1 mice. The results showed that administration of this vaccine elicits a long-lasting antibody titer, which correlated well with a reduction of Aβ burden upon histological analysis. Cognitive function in transgenic responders to the vaccine was rescued to levels similar to those found in non-transgenic mice, indicating that the vaccine is capable of providing therapeutic benefit in APP+PS1 mice when administered after the onset of AD pathology. The vaccine also shows indications of circumventing past safety problems observed in AD immunotherapy, as Th1 pro-inflammatory cytokines were not elevated after long-term vaccine administration. Moreover, microhemorrhaging and T-cell infiltration into the brain are not observed in any of the treated subjects. All in all, this vaccine has many advantages over contemporary vaccines against Alzheimer's disease, and may lead to a viable treatment for the disease in the future.
format	article
author	Neel R Nabar Fang Yuan Xiaoyang Lin Li Wang Ge Bai Jonathan Mayl Yaqiong Li Shu-Feng Zhou Jinhuan Wang Jianfeng Cai Chuanhai Cao
author_facet	Neel R Nabar Fang Yuan Xiaoyang Lin Li Wang Ge Bai Jonathan Mayl Yaqiong Li Shu-Feng Zhou Jinhuan Wang Jianfeng Cai Chuanhai Cao
author_sort	Neel R Nabar
title	Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.
title_short	Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.
title_full	Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.
title_fullStr	Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.
title_full_unstemmed	Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.
title_sort	cell therapy: a safe and efficacious therapeutic treatment for alzheimer's disease in app+ps1 mice.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/b3d47ae47c0f4d59b889ae0486f25323
work_keys_str_mv	AT neelrnabar celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT fangyuan celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT xiaoyanglin celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT liwang celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT gebai celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT jonathanmayl celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT yaqiongli celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT shufengzhou celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT jinhuanwang celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT jianfengcai celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice AT chuanhaicao celltherapyasafeandefficacioustherapeutictreatmentforalzheimersdiseaseinappps1mice
_version_	1718422252108644352

Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice.

Ejemplares similares